Literature DB >> 30730019

Epigenetic Risk Profile of Diabetic Kidney Disease in High-Risk Populations.

Lixia Xu1,2, Rama Natarajan1, Zhen Chen3.   

Abstract

PURPOSE OF REVIEW: Epigenetic variations have been shown to reveal vulnerability to diabetes and its complications. Although it has become clear that metabolic derangements, especially hyperglycemia, can impose a long-term metabolic memory that predisposes to diabetic complications, the underlying mechanisms remain to be understood. It has been suggested that epigenetics (e.g., histone modification, DNA methylation, and non-coding RNAs) help link metabolic disruption to aberrancies related to diabetic kidney disease (DKD). In this review, we discuss the key findings and advances made in the epigenetic risk profile of DKD and provide perspectives on the emerging topics that implicate epigenetics in DKD. RECENT
FINDINGS: Epigenetic profiles can be profoundly altered in patients with diabetes, in circulating blood cells as well as in renal tissues. These changes provide useful insight into the mechanisms of diabetic kidney injury and progressive kidney dysfunction. Increasing evidence supports the role of epigenetic regulation in DKD. More studies are needed to elucidate the mechanism and importance of epigenetic changes in the initiation and progression of DKD and to further explore their diagnostic and therapeutic potential in the clinical management of patients with diabetes who have a high risk for DKD.

Entities:  

Keywords:  Diabetic kidney disease; Diabetic nephropathy; Epigenetic regulation

Mesh:

Year:  2019        PMID: 30730019      PMCID: PMC6483106          DOI: 10.1007/s11892-019-1129-2

Source DB:  PubMed          Journal:  Curr Diab Rep        ISSN: 1534-4827            Impact factor:   4.810


  98 in total

1.  Epigenomic profiling reveals an association between persistence of DNA methylation and metabolic memory in the DCCT/EDIC type 1 diabetes cohort.

Authors:  Zhuo Chen; Feng Miao; Andrew D Paterson; John M Lachin; Lingxiao Zhang; Dustin E Schones; Xiwei Wu; Jinhui Wang; Joshua D Tompkins; Saul Genuth; Barbara H Braffett; Arthur D Riggs; Rama Natarajan
Journal:  Proc Natl Acad Sci U S A       Date:  2016-05-09       Impact factor: 11.205

Review 2.  Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders.

Authors:  Katrina J Falkenberg; Ricky W Johnstone
Journal:  Nat Rev Drug Discov       Date:  2014-08-18       Impact factor: 84.694

Review 3.  MicroRNA: A new generation therapeutic target in diabetic nephropathy.

Authors:  Saikat Dewanjee; Niloy Bhattacharjee
Journal:  Biochem Pharmacol       Date:  2018-06-22       Impact factor: 5.858

4.  The landscape of accessible chromatin in mammalian preimplantation embryos.

Authors:  Jingyi Wu; Bo Huang; He Chen; Qiangzong Yin; Yang Liu; Yunlong Xiang; Bingjie Zhang; Bofeng Liu; Qiujun Wang; Weikun Xia; Wenzhi Li; Yuanyuan Li; Jing Ma; Xu Peng; Hui Zheng; Jia Ming; Wenhao Zhang; Jing Zhang; Geng Tian; Feng Xu; Zai Chang; Jie Na; Xuerui Yang; Wei Xie
Journal:  Nature       Date:  2016-06-15       Impact factor: 49.962

5.  Downregulation of lncRNA MALAT1 contributes to renal functional improvement after duodenal-jejunal bypass in a diabetic rat model.

Authors:  Dong Wu; Yu-Gang Cheng; Xin Huang; Ming-Wei Zhong; Shao-Zhuang Liu; San-Yuan Hu
Journal:  J Physiol Biochem       Date:  2018-05-21       Impact factor: 4.158

6.  Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy.

Authors:  John M Lachin; Saul Genuth; Patricia Cleary; Matthew D Davis; David M Nathan
Journal:  N Engl J Med       Date:  2000-02-10       Impact factor: 91.245

7.  Risk of nephropathy can be detected before the onset of microalbuminuria during the early years after diagnosis of type 1 diabetes.

Authors:  C J Schultz; H A Neil; R N Dalton; D B Dunger
Journal:  Diabetes Care       Date:  2000-12       Impact factor: 19.112

8.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.

Authors:  D M Nathan; S Genuth; J Lachin; P Cleary; O Crofford; M Davis; L Rand; C Siebert
Journal:  N Engl J Med       Date:  1993-09-30       Impact factor: 91.245

9.  LncRNA-NR_033515 promotes proliferation, fibrogenesis and epithelial-to-mesenchymal transition by targeting miR-743b-5p in diabetic nephropathy.

Authors:  Junjie Gao; Weisong Wang; Fangli Wang; Canghui Guo
Journal:  Biomed Pharmacother       Date:  2018-07-11       Impact factor: 6.529

Review 10.  Role of Epigenetic Histone Modifications in Diabetic Kidney Disease Involving Renal Fibrosis.

Authors:  Jing Sun; Yangwei Wang; Wenpeng Cui; Yan Lou; Guangdong Sun; Dongmei Zhang; Lining Miao
Journal:  J Diabetes Res       Date:  2017-06-13       Impact factor: 4.011

View more
  3 in total

1.  Vascular Regulation by Super Enhancer-Derived LINC00607.

Authors:  Kiran Sriram; Yingjun Luo; Dongqiang Yuan; Naseeb Kaur Malhi; Alonso Tapia; Vishnu Amaram Samara; Rama Natarajan; Zhen Bouman Chen
Journal:  Front Cardiovasc Med       Date:  2022-06-28

2.  EGCG Attenuates Renal Damage via Reversing Klotho Hypermethylation in Diabetic db/db Mice and HK-2 Cells.

Authors:  Xiu Hong Yang; Bao Long Zhang; Xiao Meng Zhang; Jin Dong Tong; Yan Hong Gu; Li Li Guo; Hui Min Jin
Journal:  Oxid Med Cell Longev       Date:  2020-08-27       Impact factor: 6.543

Review 3.  The epigenetics of diabetes, obesity, overweight and cardiovascular disease.

Authors:  Harem Othman Smail
Journal:  AIMS Genet       Date:  2019-08-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.